5-(1-哌啶)-2-呋喃甲醛 | 22868-60-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-(1-哌啶)-2-呋喃甲醛
• 中文别名: 5-(1-哌啶基)呋喃-2-甲醛；N-(2-氯乙基)-N'-(3-氯-4-甲基苯基)脲
• 英文名称: 5-(piperidin-1-yl)furan-2-carbaldehyde
• 英文别名: 5-piperidino-2-furancarboxaldehyde；5-piperidinofuran-2-carboxaldehyde；5-Piperidino-2-furancarbaldehyd；5-piperidin-1-yl-furan-2-carbaldehyde；5-Piperidinofurfural；5-piperidin-1-ylfuran-2-carbaldehyde
• CAS: 22868-60-6
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD02614962
• 分子量: 179.219
• InChiKey: UEIBBOBGTJMFRM-UHFFFAOYSA-N

物化性质

• 熔点：
  50.5-51.5 °C
• 沸点：
  329.3±27.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(1-哌啶)-2-呋喃甲醛 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 2-Methyl-1-(phenylcarbamoyloxy)-N-(5-piperidinofurfuryliden)-2-propanamin-N-oxid
  参考文献：
  名称：

  Kliegel, Wolfgang; Enders, Bernhard; Becker, Harald, Chemische Berichte, 1983, vol. 116, # 1, p. 27 - 45

  摘要：

  DOI：
• 作为产物：
  描述：

  5-formyl-2-furansulfonic acid sodium salt 以37%的产率得到5-(1-哌啶)-2-呋喃甲醛
  参考文献：
  名称：

  Kliegel, Wolfgang; Enders, Bernhard; Becker, Harald, Chemische Berichte, 1983, vol. 116, # 1, p. 27 - 45

  摘要：

  DOI：

文献信息

• A facile preparation of trisubstituted amino-furan and -thiophene derivatives
  作者：Raouf Medimagh、Sylvain Marque、Damien Prim、Saber Chatti

  DOI：10.1039/c1ob05216k

  日期：——

  β-Alkylation of amino-furan and -thiophene heterocycles is described through metal-, acid- and base-free carbon–carbon bond formation. The ability of both heterocycles to undergo selective β-alkylation is compared by mean of experimental and theoretical data. The presence of chiral amine substituents induced the diastereoselective generation of the newly formed additional stereocenter.

  β-烷基化 氨基呋喃-噻吩杂环通过无金属，无酸和无碱的碳-碳键形成来描述。通过实验和理论数据比较了两个杂环进行选择性β-烷基化的能力。手性胺取代基的存在诱导了新形成的另外的立体中心的非对映选择性的产生。
• HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor)
  申请人：GENESTE Herve

  公开号：US20080300260A1

  公开（公告）日：2008-12-04

  The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

  本发明涉及异环化合物，这些化合物是代谢型谷氨酸受体的阳性调节剂。本发明还涉及使用这些化合物制备药物组合物以及治疗神经系统和精神疾病的方法，这些疾病与谷氨酸功能障碍有关。
• Small Heterocyclic D‐π‐D‐π‐A Push‐Pull Molecules with Complex Electron Donors
  作者：Jiří Kulhánek、Oldřich Pytela、Filip Bureš、Milan Klikar

  DOI：10.1002/ejoc.202100137

  日期：2021.6.14

  Small push-pull molecules based on N,N-dibutylthiobarbituric electron-withdrawing unit and a combined electron donor have been designed and synthesized. Thiophene, N-methylpyrrole, and furan auxiliary donors were employed as central π-linkers accompanied by methoxy and amino mesomeric donors. Thorough structure-property relationships were investigated using both experimental and theoretical methods.

  设计并合成了基于N , N-二丁基硫代巴比妥类吸电子单元和组合电子供体的推拉小分子。噻吩、N-甲基吡咯和呋喃辅助供体被用作中心 π-接头，并伴随有甲氧基和氨基内聚体供体。使用实验和理论方法研究了彻底的结构-性能关系。
• Amide compounds and methods of using the same
  申请人：Thompson K. Scott

  公开号：US20050113580A1

  公开（公告）日：2005-05-26

  Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.

  本发明揭示了一种具有以下结构式的化合物：其药学上可接受的盐或溶剂，以及包含该化合物的制药组合物，其中结构变量如本文所定义。本发明的化合物、盐和溶剂作为LXR激动剂有用。
• BCRP/ABCG2 INHIBITOR
  申请人：Yamazaki Ryuta

  公开号：US20090253656A1

  公开（公告）日：2009-10-08

  The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R 1 and R 2 represents a cyano group and the other represents a hydrogen atom; Ar 1 represents a group selected from among the groups represented by formulas (2) to (4): and Ar 2 represents an aromatic hydrocarbon group having a condensed ring which may be substituted by a halogen atom, or a group selected from among the groups represented by the following formulas (5) to (15): or a salt thereof.

  该发明涉及一种乳腺癌耐药蛋白（BCRP/ABCG2）抑制剂。该BCRP抑制剂包含以下化合物作为活性成分，其化学式为（1）：其中R1和R2中的一个代表氰基，另一个代表氢原子；Ar1代表从以下化学式（2）至（4）中选出的一种基团：Ar2代表一种含有可能被卤素原子取代的融合环的芳香烃基团，或者从以下化学式（5）至（15）中选出的一种基团：或其盐。

表征谱图